A study in prostate cancer cells demonstrated high expression of RAP1GDS1 in cells under hypoxia and postulated that targeting it and similar CLK kinases may provide benefit in the treatment of cancers in which tumour hypoxia contributes to resistance to therapy [64]. This evidence concerns the gene RAP1GDS1 and prostate cancer.